CEST- Glucose Enhanced MRI for Metastatic Brain Tumours

• Status: Terminated
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This project will compare two MRI contrast agents in metastatic brain tumours in humans. More specifically, the investigators will compare the tumour contrast obtained using glucose versus the current standard gadolinium-based contrast agent (GBCA, gadobutrol, trade name Gadovist, will be used).

First, participants will receive a glucose bolus injection followed by glucose enhanced MRI. Second, participants will receive a Gd-DTPA bolus injection followed by Gd-DTPA enhanced MRI. Both contrast studies will be performed during the same MRI study, which will be under one hour long.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: British Columbia Cancer Agency
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Male or females

• Between 18 and 65 years of age

• Of all ethnic groups

• BCCA participants with at least one contrast enhancing brain mass with a diameter ≥ 1 cm and consistent with metastatic carcinoma*

• Able to give consent

• Willingness to participate in the study * One additional healthy participant will be included in the study to perform a 'test-run' for the complicated MRI and infusion protocol.

Exclusion Criteria:

• Pregnancy

• Diabetes mellitus (self-reported or HbA1C ≥ 6.5%)

• Ferromagnetic implant or foreign metallic bodies (pacemaker, loose metal, etc.)

• Claustrophobia

• History of kidney disease and/or eGFR < 60

• Abnormal fasting blood glucose (<70mg/dL or >125 mg/dL)

• Allergic to corn

• History of adverse reactions to gadolinium based contrast agents

• Poor performance status (Karnofsky PS<70%)

• Previously received whole brain radiotherapy

• All lesions evident on imaging were previously treated with stereotactic radiosurgery

• The participants weigh more than 300lbs

• The participants had surgery in the last 6 weeks

• The participants have an intrauterine device

• The participants have cosmetic tattoos